Latest Period
Q1 2026
Security Snapshot
Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) Institutional Ownership
CUSIP: 74065P101
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
55
Shares (Excl. Options)
30,772,368
Price
$3.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- PRLD on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 30,772,368
- Total 13F value
- $105,239,465
- Portfolio coverage rank
- 0%
- Share change
- +2,321,660
- Value change
- +$8,578,948
- Number of holders
- 55
- Shares outstanding
- 65,427,364
- SEC-reported price per share
- $4.64
- Insider filing price
- $4.64
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share is tracked under CUSIP 74065P101.
- 55 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 48 to 55 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $82,563,685 to $105,239,465.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 55 institutions filings for Q1 2026.
Security key
74065P101
Latest holder period
Q1 2026
13F holders
55
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
PRLD full holder history
Prelude Therapeutics Inc SEC filings
Prelude Therapeutics Inc company facts
Prelude Therapeutics Inc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74065P101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PRLD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 16% | $44,259,932 | 12,935,071 | ORBIMED ADVISORS LLC | 21 Apr 2026 | |||
| BAKER BROS. ADVISORS LP | 16% | -33% | $35,227,431 | +$86,682 | 10,295,301 | +0.25% | Baker Bros. Advisors LP | 20 Apr 2026 |
| Vaddi Krishna | 13% | -4.6% | $19,562,376 | +$1,008,643 | 6,745,647 | +5.4% | Vaddi Krishna | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $22,157,579 | 6,477,309 | RA Capital Management, L.P. | 21 Apr 2026 | |||
| INCYTE CORP | 9.9% | $6,295,859 | 4,372,124 | INCYTE CORP | 03 Nov 2025 |
As of 31 Mar 2026, 55 institutional investors reported holding 30,772,368 shares of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD). This represents 47% of the company’s total 65,427,364 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 17% | 10,909,256 | 0% | 0.84% | $37,309,656 |
| BAKER BROS. ADVISORS LP | 15% | 10,123,824 | 0% | 0.2% | $34,623,478 |
| Kynam Capital Management, LP | 2.4% | 1,592,551 | +102% | 0.35% | $5,446,524 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9% | 1,230,406 | 0% | 0% | $4,207,989 |
| EcoR1 Capital, LLC | 1.4% | 947,049 | 0.14% | $3,238,908 | |
| TWO SIGMA INVESTMENTS, LP | 1.4% | 923,626 | +17% | 0% | $3,158,801 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.85% | 558,339 | +355% | 0.33% | $1,909,519 |
| ACADIAN ASSET MANAGEMENT LLC | 0.78% | 511,519 | -4.5% | 0% | $1,747,000 |
| MILLENNIUM MANAGEMENT LLC | 0.58% | 382,737 | +153% | 0% | $1,308,961 |
| MARSHALL WACE, LLP | 0.55% | 358,906 | +31% | 0% | $1,227,458 |
| MORGAN STANLEY | 0.49% | 322,161 | -3.8% | 0% | $1,101,790 |
| BlackRock, Inc. | 0.49% | 321,886 | +21% | 0% | $1,100,850 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.46% | 302,458 | +11% | 0% | $1,034,847 |
| RENAISSANCE TECHNOLOGIES LLC | 0.42% | 275,200 | +1.4% | 0% | $941,184 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.41% | 267,788 | +97% | 0% | $915,835 |
| GOLDMAN SACHS GROUP INC | 0.36% | 236,469 | +101% | 0% | $808,724 |
| JANE STREET GROUP, LLC | 0.29% | 192,963 | +74% | 0% | $659,933 |
| VANGUARD FIDUCIARY TRUST CO | 0.24% | 157,380 | 0% | 0% | $538,240 |
| ADAR1 Capital Management, LLC | 0.23% | 152,825 | 0.03% | $522,662 | |
| STATE STREET CORP | 0.21% | 138,231 | +8.6% | 0% | $472,750 |
| CITADEL ADVISORS LLC | 0.19% | 124,378 | 0% | $425,373 | |
| Connor, Clark & Lunn Investment Management Ltd. | 0.17% | 109,085 | +137% | 0% | $373,071 |
| UBS Group AG | 0.1% | 64,505 | +3374% | 0% | $220,607 |
| HRT FINANCIAL LP | 0.09% | 58,699 | 0% | $200,000 | |
| XTX Topco Ltd | 0.09% | 57,190 | +14% | 0% | $195,590 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 30,772,368 | $105,239,465 | +$8,578,948 | $3.42 | 55 |
| 2025 Q4 | 28,472,272 | $82,563,685 | +$4,105,694 | $2.90 | 48 |
| 2025 Q3 | 27,161,835 | $39,111,943 | +$249,044 | $1.44 | 45 |
| 2025 Q2 | 27,187,955 | $21,995,839 | -$2,401,932 | $0.81 | 49 |
| 2025 Q1 | 30,289,302 | $23,267,043 | -$2,260,767 | $0.77 | 56 |
| 2024 Q4 | 32,136,788 | $40,964,573 | -$12,964,360 | $1.28 | 60 |
| 2024 Q3 | 35,754,682 | $74,021,916 | +$3,111,676 | $2.07 | 69 |
| 2024 Q2 | 33,917,161 | $129,220,239 | -$1,353,555 | $3.81 | 59 |
| 2024 Q1 | 34,197,005 | $162,095,049 | -$2,346,403 | $4.74 | 56 |
| 2023 Q4 | 34,725,223 | $148,268,893 | -$6,317,081 | $4.27 | 55 |
| 2023 Q3 | 36,614,209 | $113,138,241 | +$1,036,814 | $3.09 | 57 |
| 2023 Q2 | 36,273,689 | $163,232,997 | +$31,250,061 | $4.50 | 52 |
| 2023 Q1 | 31,510,272 | $179,609,477 | +$1,734,926 | $5.70 | 54 |
| 2022 Q4 | 31,178,634 | $188,300,136 | -$4,385,760 | $6.04 | 59 |
| 2022 Q3 | 31,821,580 | $210,332,653 | -$5,208,246 | $6.61 | 50 |
| 2022 Q2 | 32,736,159 | $170,877,689 | -$7,216,025 | $5.22 | 55 |
| 2022 Q1 | 34,109,145 | $235,382,986 | -$10,995,652 | $6.90 | 64 |
| 2021 Q4 | 35,151,511 | $437,636,391 | -$26,977,029 | $12.45 | 74 |
| 2021 Q3 | 35,967,344 | $1,123,981,157 | +$47,268,239 | $31.25 | 61 |
| 2021 Q2 | 34,458,535 | $986,644,054 | +$52,903,899 | $28.63 | 56 |
| 2021 Q1 | 32,543,650 | $1,410,113,760 | -$96,898,538 | $43.33 | 60 |
| 2020 Q4 | 34,651,491 | $2,474,382,581 | +$136,089,518 | $71.55 | 51 |
| 2020 Q3 | 33,322,061 | $999,836,330 | +$999,836,330 | $30.13 | 38 |